Literature DB >> 30187821

Anxiety Independently Contributes to Severity of Freezing of Gait in People With Parkinson's Disease.

Milla Pimenta1, Dandara Moreira1, Taísa Nogueira1, Carolina Silva1, Elen B Pinto1, Guilherme T Valenca1, Lorena R S Almeida1.   

Abstract

Freezing of gait is a disabling feature of Parkinson's disease, and it has been shown that nonmotor symptoms, such as anxiety and cognitive impairment, may be involved in the pathophysiology of the phenomenon. However, the association between freezing of gait severity and nonmotor symptoms is yet to be determined. Therefore, the overall aim of this study was to determine factors that contribute to severity of freezing of gait in people with Parkinson's disease. Participants (N=78) were assessed by disease-specific and self-report measures, including the Hospital Anxiety and Depression Scale (HADS), the Montreal Cognitive Assessment, and the Freezing of Gait Questionnaire (FOG-Q). Participants were classified as "freezers" if they scored ≥1 on item 3 of the FOG-Q; the sum of items 3-6 was used to determine freezing of gait severity. Freezers (N=27) showed higher scores on the HADS anxiety (p=0.002) and HADS depression (p=0.006) subscales. A multivariate linear model showed that disease severity (as measured by using the modified Hoehn and Yahr scale) accounted for 31% of the variance in FOG-Q severity scores (p<0.001). The presence of HADS anxiety ≥8 points increased the explained variance to 38% (p=0.010), and the full model (reached by adding the levodopa equivalent dose) explained 42% of the variance in freezing of gait severity (p=0.026). The findings provide additional support for the contribution of anxiety to greater freezing of gait severity, taking into account not only the frequency but the duration of the episodes, and suggest that anxiety should be routinely evaluated in people with Parkinson's disease who present with freezing of gait.

Entities:  

Keywords:  Anxiety Disorders (Neuropsychiatric Aspects); Freezing of Gait; Parkinson’s Disease

Mesh:

Year:  2018        PMID: 30187821     DOI: 10.1176/appi.neuropsych.17090177

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  6 in total

1.  A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.

Authors:  Ruth B Schneider; Peggy Auinger; Christopher G Tarolli; Julia Iourinets; María Cristina Gil-Díaz; Irene H Richard
Journal:  Parkinsonism Relat Disord       Date:  2020-10-13       Impact factor: 4.891

Review 2.  Prevalence of freezing of gait in Parkinson's disease: a systematic review and meta-analysis.

Authors:  Wei-Shan Zhang; Chao Gao; Yu-Yan Tan; Sheng-Di Chen
Journal:  J Neurol       Date:  2021-07-08       Impact factor: 4.849

3.  Assessment of Health-Related Quality of Life between People with Parkinson's Disease and Non-Parkinson's: Using Data Drawn from the '100 for Parkinson's' Smartphone-Based Prospective Study.

Authors:  Xiaojing Fan; Duolao Wang; Bruce Hellman; Mathieu F Janssen; Gerben Bakker; Rupert Coghlan; Amelia Hursey; Helen Matthews; Ian Whetstone
Journal:  Int J Environ Res Public Health       Date:  2018-11-13       Impact factor: 3.390

Review 4.  Relationship between Freezing of Gait and Anxiety in Parkinson's Disease Patients: A Systemic Literature Review.

Authors:  Ivan Witt; Hooman Ganjavi; Penny MacDonald
Journal:  Parkinsons Dis       Date:  2019-07-24

5.  Pedunculopontine Nucleus Dysconnectivity Correlates With Gait Impairment in Parkinson's Disease: An Exploratory Study.

Authors:  Stephen Joza; Richard Camicioli; W R Wayne Martin; Marguerite Wieler; Myrlene Gee; Fang Ba
Journal:  Front Aging Neurosci       Date:  2022-07-08       Impact factor: 5.702

Review 6.  Spinal Cord Stimulation for Freezing of Gait: From Bench to Bedside.

Authors:  Erich Talamoni Fonoff; Andrea C de Lima-Pardini; Daniel Boari Coelho; Bernardo Assumpção Monaco; Birajara Machado; Carolina Pinto de Souza; Maria Gabriela Dos Santos Ghilardi; Clement Hamani
Journal:  Front Neurol       Date:  2019-08-27       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.